Islet β-cytotoxic monoclonal antibody against glycolipids in experimental diabetes induced by low dose streptozotocin and Freund's adjuvant
(1988) In Journal of Immunology 140(12). p.4144-4150- Abstract
Diabetes was induced in BALB/c mice by four injections of a subdiabetogenic dose (40 mg/kg) of streptozotocin in combination with CFA. The treatment increased the plasma glucose from 5.8 ± 0.1 to 22.1 ± 1.3 mmol/liter (n = 9). The diabetic animals had circulating islet cell surface antibodies (75%), and a monoclonal islet cell surface IgM antibody, K56aF3, generated from one of the diabetic BALB/c mice, mediated C-Dependent cytotoxicity against insulin-producing cells and inhibited glucose-stimulated insulin release from isolated rat islets. Solid phase assay on thin layer chromatograms showed no binding of the K56aF3 antibody to glycolipids prepared from relevant cells. However, testing against a series of glycolipids of various... (More)
Diabetes was induced in BALB/c mice by four injections of a subdiabetogenic dose (40 mg/kg) of streptozotocin in combination with CFA. The treatment increased the plasma glucose from 5.8 ± 0.1 to 22.1 ± 1.3 mmol/liter (n = 9). The diabetic animals had circulating islet cell surface antibodies (75%), and a monoclonal islet cell surface IgM antibody, K56aF3, generated from one of the diabetic BALB/c mice, mediated C-Dependent cytotoxicity against insulin-producing cells and inhibited glucose-stimulated insulin release from isolated rat islets. Solid phase assay on thin layer chromatograms showed no binding of the K56aF3 antibody to glycolipids prepared from relevant cells. However, testing against a series of glycolipids of various non-pancreatic origins showed a preferential binding to a nine-sugar glycolipid isolated from human erythrocytes carrying an unusual blood group A determinant (type 3). It is suggested that this mAb may be associated with the development of diabetes following a combination of polyclonal activation and non-diabetogenic doses of streptozotocin.
(Less)
- author
- Ziegler, M. ; Teneberg, S. ; Witt, S. ; Ziegler, B. ; Hehmke, B. ; Kohnert, K. D. ; Egeberg, J. ; Karlsson, K. A. and Lernmark, A. LU
- publishing date
- 1988-01-01
- type
- Contribution to journal
- publication status
- published
- in
- Journal of Immunology
- volume
- 140
- issue
- 12
- pages
- 7 pages
- publisher
- American Association of Immunologists
- external identifiers
-
- pmid:2967328
- scopus:0023705399
- ISSN
- 0022-1767
- language
- English
- LU publication?
- no
- id
- 9d3a497a-e98b-4332-8b55-eb3c1d427960
- date added to LUP
- 2019-09-11 10:06:03
- date last changed
- 2024-03-13 08:16:29
@article{9d3a497a-e98b-4332-8b55-eb3c1d427960, abstract = {{<p>Diabetes was induced in BALB/c mice by four injections of a subdiabetogenic dose (40 mg/kg) of streptozotocin in combination with CFA. The treatment increased the plasma glucose from 5.8 ± 0.1 to 22.1 ± 1.3 mmol/liter (n = 9). The diabetic animals had circulating islet cell surface antibodies (75%), and a monoclonal islet cell surface IgM antibody, K56aF3, generated from one of the diabetic BALB/c mice, mediated C-Dependent cytotoxicity against insulin-producing cells and inhibited glucose-stimulated insulin release from isolated rat islets. Solid phase assay on thin layer chromatograms showed no binding of the K56aF3 antibody to glycolipids prepared from relevant cells. However, testing against a series of glycolipids of various non-pancreatic origins showed a preferential binding to a nine-sugar glycolipid isolated from human erythrocytes carrying an unusual blood group A determinant (type 3). It is suggested that this mAb may be associated with the development of diabetes following a combination of polyclonal activation and non-diabetogenic doses of streptozotocin.</p>}}, author = {{Ziegler, M. and Teneberg, S. and Witt, S. and Ziegler, B. and Hehmke, B. and Kohnert, K. D. and Egeberg, J. and Karlsson, K. A. and Lernmark, A.}}, issn = {{0022-1767}}, language = {{eng}}, month = {{01}}, number = {{12}}, pages = {{4144--4150}}, publisher = {{American Association of Immunologists}}, series = {{Journal of Immunology}}, title = {{Islet β-cytotoxic monoclonal antibody against glycolipids in experimental diabetes induced by low dose streptozotocin and Freund's adjuvant}}, volume = {{140}}, year = {{1988}}, }